Overview

A Pilot Study of Pyridostigmine in Pompe Disease

Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant treatment for people with Pompe disease, as it increases the functional impact of this neurotransmitter. Hypothesis: the use of pyridostigmine in Pompe disease will improve transmission of acetylcholine across the neuromuscular junction, skeletal muscle function, respiratory function, and quality of life.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Florida
Treatments:
Bromides
Cholinesterase Inhibitors
Pyridostigmine Bromide